This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Grifols (GRFS) Surges: Stock Moves 5.4% Higher
by Zacks Equity Research
Grifols (GRFS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Is Grifols, S.A. (GRFS) a Great Stock for Value Investors?
by Zacks Equity Research
Is Grifols, S.A. (GRFS) a great pick from the value investor's perspective right now? Read on to know more.
Henry Schien to Distribute Grifols Product in United States
by Zacks Equity Research
We expect Henry Schien's (HSIC) partnership with Grifols to be strategically accretive to its portfolio given the rising demand for saline products in U.S. market.
Should Value Investors Consider Grifols (GRFS) Stock Now?
by Zacks Equity Research
Is Grifols (GRFS) a great pick from the value investor's perspective right now? Read on to know more.
Should Value Investors Consider Grifols (GRFS) Stock Right Now?
by Zacks Equity Research
Is Grifols a great pick from the value investor's perspective right now? Read on to know more.
VIVUS (VVUS) Loss Narrower than Expected, Revenues Up Y/Y
by Zacks Equity Research
VIVUS Inc. (VVUS) reported a loss of 1 cent per share in the first quarter of 2017, which was narrower than a loss of 12 cents in the year-ago period as well as the Zacks Consensus Estimate of a loss of 13 cents
Akebia Therapeutics (AKBA) Shows Strength: Stock Up 5.8%
by Zacks Equity Research
Akebia Therapeutics, Inc. (AKBA) shares rose almost 6% in the last trading session.
Glaxo (GSK) Reports In-Line Q1 Earnings, Reiterates View
by Zacks Equity Research
GlaxoSmithKline plc's (GSK) first quarter results came roughly in line with expectations. Glaxo reported first-quarter 2017 core earnings of 62 cents per American Depositary Share (ADS), in line with the Zacks Consensus Estimate.
Celgene (CELG) Tops on Q1 Earnings, Sales Miss, Raises View
by Zacks Equity Research
Celgene's (CELG) first-quarter results were mixed, with the company beating on earnings but missing on sales.
AbbVie (ABBV) Presents Positive Data on HCV Combination Drug
by Zacks Equity Research
AbbVie Inc. (ABBV) announced that data from two phase III studies, EXPEDITION-1 and ENDURANCE-3, evaluating its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P) for all genotypes of Hepatitis C virus (HCV)
Nivalis' (NVLS) Shares Down After Merger Deal with Alpine
by Zacks Equity Research
The announcement of Nivalis Therapeutics, Inc.'s (NVLS) merger agreement with a privately-held biotechnology company, Alpine Immune Sciences, Inc. failed to excite investors.
Zacks.com featured highlights: Arbor Realty, Commercial Vehicle Group, Grifols, S.A., Match Group and Xcerra
by Zacks Equity Research
Zacks.com featured highlights: Arbor Realty, Commercial Vehicle Group, Grifols, S.A., Match Group and Xcerra
GENOCEA BIOSCIENCES (GNCA) Catches Eye: Stock Gains 7.1%
by Zacks Equity Research
GENOCEA BIOSCIENCES, INC. (GNCA) moved big last session, as its shares rose over 7% on the day.
How to Uncover Institutional Buying
by Kevin Matras
Kevin Matras goes over how to screen for weekly volume increases to uncover institutional buying. Highlighted stocks include ABR, CVGI, GRFS, MTCH and XCRA.
AMAG Files for FDA Approval of Subcutaneous Form of Makena
by Zacks Equity Research
AMAG Pharmaceuticals, Inc. (AMAG) announced the submission of a supplemental New Drug Application (sNDA) to the FDA for the subcutaneous auto-injector form of its marketed drug Makena in the U.S.
Ohr Pharmaceutical (OHRP) Jumps: Stock Adds 15% in Session
by Zacks Equity Research
Ohr Pharmaceutical, Inc. (OHRP) moved big last session, as its shares jumped 15% on the day.
Infinity Pharmaceuticals (INFI) Looks Good: Stock Jumps 19%
by Zacks Equity Research
Infinity Pharmaceuticals, Inc. (INFI) shares rose over 19% in the last trading session.
TherapeuticsMD Falls on Likely Delay in TX-004HR Approval
by Zacks Equity Research
Shares of TherapeuticsMD, Inc. (TXMD) have declined almost 25% since Monday when it received a letter from the FDA identifying deficiencies in the new drug application (NDA) for its dyspareunia drug, TX-400HR filed last July
Galectin Therapeutics (GALT) Looks Good: Stock Jumps 16.7%
by Zacks Equity Research
Galectin Therapeutics, Inc. (GALT) shares rose nearly 17% in the last trading session.
Amgen Files for Xgeva Label Expansion, To Include Myeloma
by Zacks Equity Research
Amgen, Inc. (AMGN) recently announced that it has submitted a supplemental Biologics License Application (sBLA) to the FDA to expand the label of its key drug, Xgeva.
Sanofi's (SNY) Diabetes Drug Toujeo Lowers Hypoglycemia Risk
by Zacks Equity Research
A real-world observational study showed that when type 2 diabetes patients on basal insulin switched to Toujeo, it led to a significant reduction in risk of hypoglycemia without compromising blood sugar control
AbbVie's (ABBV) Humira Drug Label Update Approved by FDA
by Zacks Equity Research
AbbVie Inc.'s (ABBV) announced that the FDA has approved the inclusion of moderate to severe fingernail psoriasis data on the label of AbbVie???s multi-utility TNF blocker drug, Humira
New Strong Buy Stocks for March 30th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
Catalyst Pharmaceuticals (CPRX) Jumps: Stock Gains 18.2%
by Zacks Equity Research
Catalyst Pharmaceuticals, Inc. (CPRX) moved big last session, as its shares rose over 18% on the day.
5 Cheap PEG Picks for Value Investors Right Now
by Zacks Equity Research
PEG is the ratio with the earnings growth component in it.